Inhibrx Biosciences INBX
NASDAQ INBX
$97.10 -1.09 (-1.11%)
At close: Oct 22, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) EBIT (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) recorded EBIT of -$32.15 million in Q2 2026, compared with -$27.39 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBIT (2023 - 2026) Analysis & Trends

On a TTM basis, Inhibrx Biosciences' EBIT came in at -$124.27 million as of Jun 30, 2026; for FY2025, it came in at -$135.03 million.

  • Across earlier years, EBIT came in at -$331.45 million in FY2024 and -$219.22 million in FY2023.
  • Quarterly EBIT has ranged from -$160.9 million in Q2 2024 to -$27.39 million in Q2 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 6.18 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 6.43 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 3.16 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -10.39 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 4.27 Bn
10 Inhibrx Biosciences 1.52 Bn 923.96 Mn - -32.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.15 Mn
Dec 31, 2025 -30.92 Mn
Sep 30, 2025 -33.81 Mn
Jun 30, 2025 -27.39 Mn
Mar 31, 2025 -42.90 Mn
Dec 31, 2024 -49.93 Mn
Sep 30, 2024 -46.80 Mn
Jun 30, 2024 -160.90 Mn
Mar 31, 2024 -73.83 Mn
Dec 31, 2023 -88.29 Mn
Sep 30, 2023 -45.83 Mn
Jun 30, 2023 -41.34 Mn
API Access

Inhibrx Biosciences EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=INBX&period=max&api_key=YOUR_API_KEY